HSA exhibits both i) passive tumor targeting due to its enhanced permeability and retention (EPR) effect, and ii) active targeting due to HSA receptors that are overexpressed on cancer cells, such as the albumin-binding protein SPARC (secreted protein acidic and rich in cysteine) and gp60 (a 60-kDa sialoglycoprotein) [30]. Here, ALB is linked to cancer.